The folic acid metabolite L-5-methyltetrahydrofolate effectively reduces total serum homocysteine level in orthotopic liver transplant recipients: a double-blind placebo-controlled study
The folic acid metabolite L-5-methyltetrahydrofolate effectively reduces total serum homocysteine level in orthotopic liver transplant recipients: a double-blind placebo-controlled study
复制标题
DOI：
10.1038/sj.ejcn.1602778
复制
发表时间：
2008-06-01
影响因子：
4.7
通讯作者：
Faust, D.
中科院分区：
文献类型：
--
作者：
Akoglu, B.;Schrott, M.;Faust, D.
目的：高同型半胱氨酸血症是一种已知的心血管疾病危险因素。本研究的目的是在一项双盲安慰剂对照研究中，用l -5-甲基四氢叶酸（L-5-MTHF; 1mg）、叶酸（1mg）和安慰剂治疗肝移植受者的高同型半胱氨酸血症，并比较这些患者对L-5-MTHF和叶酸的相对反应性。受试者/方法：从法兰克福约翰沃尔夫冈歌德大学肝脏移植科招募患者。60例患者纳入本研究，12例患者因不同原因退出。患者接受了超过8周的补充L-5-MTHF或叶酸或安慰剂治疗。除常规实验室检测外，采用高效液相色谱法分析血清同型半胱氨酸（HCY）。结果：我们观察到L-5-MTHF组在研究期间(第0周：15 +/- 7.7 μ M； 8周后：9.41 +/- 2.6 μ M， P
Objective: Hyperhomocysteinemia is a described risk factor of cardiovascular diseases. The aim of this study was the treatment of hyperhomocysteinemia in liver transplant recipients with L-5-methyltetrahydrofolate (L-5-MTHF; 1 mg) vs folic acid (1 mg) vs placebo in a double-blind placebo-controlled study and to compare the relative responsiveness of these patients to L-5-MTHF and folic acid.Subjects/Methods: Patients were recruited from Hepatology-Transplantation-Unit at Johann Wolfgang Goethe-University, Frankfurt. Sixty patients were included in this study and 12 patients dropped out for different reasons. The patients were treated over 8 weeks with supplemental L-5-MTHF or folic acid or placebo. Serum homocysteine (HCY) was analyzed with high-performance liquid chromatography (HPLC) beside routine lab tests.Results: We observed only a significant decrease of total serum HCY in the L-5-MTHF group during the study period (at week 0: 15 +/- 7.7 mu M; after 8 weeks treatment: 9.41 +/- 2.6 mu M, P